Why Biological Foundation Models Are Becoming the Next Platform for Drug Discovery

Artificial intelligence has already changed how scientists search for new medicines.

Over the past five years, AI has helped researchers predict protein structures, identify potential drug targets, optimize molecular designs, and analyze biological data at a scale that was previously impossible. These advances have accelerated parts of the drug discovery process and attracted billions of dollars in investment.

Now the industry is entering a new phase.

Instead of building AI models that solve individual scientific problems, researchers are developing biological foundation models that learn from many different types of biological data at once. The goal is to create AI systems capable of understanding biology in much the same way large language models understand human language.

Recent work from companies including GenBio AI, alongside continued progress from organizations such as Isomorphic Labs, EvolutionaryScale, Recursion, and Insilico Medicine, highlights how quickly this field is evolving.

The story is not about one company introducing a better model.

It is about an entirely new approach to computational biology.

For pharmaceutical companies, biotechnology startups, investors, and researchers, biological foundation models could become one of the defining technologies of the next decade.

Drug Discovery Is Moving Beyond Specialized AI

The first generation of AI in life sciences was highly specialized.

Researchers trained individual models to predict protein folding, identify biomarkers, estimate molecular properties, or screen millions of compounds against a biological target.

These systems produced meaningful scientific advances.

However, they also reflected the fragmented nature of biological research.

Each model focused on a single task.

Each dataset answered a specific question.

Each research team often built its own AI pipeline.

While this approach continues to produce valuable discoveries, scientists increasingly recognize its limitations.

Biology is an interconnected system.

Genes influence proteins.

Proteins regulate cells.

Cells communicate with tissues.

Tissues form organs.

Disease emerges from interactions across every one of these biological layers.

Understanding only one layer rarely provides the complete picture.

That realization is driving the development of biological foundation models.

What Is a Biological Foundation Model?

Large language models learn patterns across billions of words.

Biological foundation models learn patterns across billions of biological observations.

Instead of predicting the next word in a sentence, they learn relationships between DNA sequences, RNA expression, protein structures, molecular interactions, cellular behavior, imaging data, and clinical information.

The objective is not simply to answer one scientific question.

It is to create a general-purpose AI system capable of supporting many different research tasks.

Scientists may eventually use a single biological foundation model to:

Predict protein function.
Design therapeutic molecules.
Simulate cellular responses.
Identify biomarkers.
Analyze patient datasets.
Support precision medicine.
Optimize experimental design.

Rather than training separate models for every application, researchers can adapt one foundational system to many different scientific problems.

That approach closely mirrors how foundation models transformed natural language processing.

A New Generation of AI-Native Biology Companies

Several companies are helping define this emerging field.

GenBio AI is developing multimodal biological foundation models designed to understand biology across multiple scales. Its research emphasizes virtual cell models that aim to simulate biological processes rather than simply predict isolated outcomes.

Isomorphic Labs, backed by Alphabet, combines advances in protein structure prediction with large-scale AI systems intended to accelerate therapeutic discovery.

EvolutionaryScale focuses on biological language models capable of generating and reasoning about proteins.

Recursion has built one of the world’s largest biological datasets by combining automation, imaging, and machine learning to better understand disease mechanisms.

Insilico Medicine continues expanding its generative AI platform across target discovery, molecular design, and clinical development.

Companies such as Generate:Biomedicines, Absci, and Owkin are exploring complementary approaches that combine foundation models with experimental biology, protein engineering, and multimodal clinical data.

Although their scientific strategies differ, they share a common objective.

Use AI to build a deeper understanding of biology rather than solving isolated research tasks.

Data Is Becoming the Competitive Advantage

Foundation models require enormous amounts of data.

Life sciences generates more biological information than ever before through genomic sequencing, high-content imaging, electronic laboratory notebooks, clinical trials, real-world evidence, and molecular simulations.

The challenge is that much of this information remains fragmented.

Research organizations often maintain separate systems for laboratory experiments, omics datasets, clinical operations, manufacturing, and regulatory documentation.

Building a powerful biological model requires connecting these datasets into a coherent scientific foundation.

This is why enterprise software companies are becoming increasingly important to the future of AI-driven drug discovery.

Enterprise Platforms Will Shape AI Adoption

Scientific AI does not exist in isolation.

Models must integrate into the workflows pharmaceutical companies use every day.

Platforms such as Benchling provide centralized scientific data management for research organizations.

Veeva Systems, IQVIA, Medidata, and Oracle Health manage critical clinical, regulatory, and commercial workflows.

Meanwhile, cloud providers including Microsoft Azure, AWS, and Google Cloud continue expanding infrastructure designed specifically for healthcare and life sciences.

NVIDIA BioNeMo offers optimized infrastructure and frameworks for developing biological AI models at scale.

Together, these platforms create the enterprise environment where biological foundation models can move from research papers into production.

Without connected infrastructure, even the most capable AI models struggle to deliver enterprise value.

Why Pharmaceutical Companies Should Pay Attention

Drug discovery has traditionally been a sequential process.

Scientists identify a target.

Chemists design molecules.

Biologists perform experiments.

Clinical researchers evaluate safety and efficacy.

Each team contributes expertise at different stages.

Biological foundation models have the potential to connect these stages more closely.

Rather than optimizing one step at a time, AI may eventually help researchers understand relationships across the entire discovery pipeline.

That does not replace laboratory science.

Instead, it helps scientists prioritize experiments, identify promising directions earlier, and reduce costly trial-and-error.

Organizations that begin building the infrastructure necessary to support these models today may be better positioned as the technology matures.

The Challenges Are Just Beginning

Despite rapid progress, biological foundation models remain in the early stages of development.

Scientific validation remains essential.

Experimental results must continue to confirm computational predictions.

Regulatory agencies will require evidence that AI-assisted discoveries meet the same standards as traditional research.

Data quality also remains one of the industry’s biggest challenges.

Incomplete, inconsistent, or poorly annotated datasets limit model performance regardless of algorithmic sophistication.

Interoperability between research platforms continues to be another significant obstacle.

These challenges are substantial.

They are also solvable.

As the underlying infrastructure improves, biological foundation models are likely to become increasingly useful across pharmaceutical research and development.

Looking Ahead

The next chapter of AI in life sciences is unlikely to be defined by a single algorithm or company.

It will be defined by platforms capable of learning from biology itself.

Companies such as GenBio AI, Isomorphic Labs, EvolutionaryScale, Recursion, Insilico Medicine, Generate:Biomedicines, Absci, and Owkin are exploring different paths toward that objective.

At the same time, enterprise technology providers including Benchling, Veeva Systems, IQVIA, Medidata, Oracle Health, Microsoft, AWS, Google Cloud, and NVIDIA are building the infrastructure required to bring these scientific advances into everyday pharmaceutical workflows.

Just as large language models changed how AI understands text, biological foundation models may fundamentally change how AI understands living systems.

The organizations that invest early in data infrastructure, scientific interoperability, and AI governance will be in the strongest position to benefit as this new generation of biological AI matures.

Key Takeaways

Biological foundation models are shifting AI from specialized scientific tools to general-purpose biological intelligence.
Companies including GenBio AI, Isomorphic Labs, EvolutionaryScale, and Recursion are pursuing different approaches to foundation models for biology.
Enterprise data infrastructure is becoming as important as model architecture.
Connected research platforms will play a critical role in scaling AI across pharmaceutical organizations.
The long-term value of biological AI will depend on high-quality data, scientific validation, and enterprise integration.

What to Watch Next

New multimodal biological foundation models capable of reasoning across multiple biological data types.
Partnerships between AI-native biotechnology companies and large pharmaceutical organizations.
Greater adoption of enterprise scientific data platforms.
Continued investment in cloud infrastructure optimized for biological AI.
Advances in virtual cell modeling and AI-driven simulation of complex biological systems.